UBS Group’s Esperion Therapeutics ESPR Stock Holding History

UBS Group’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-50,000	Closed	-$1.58M	–	8039
2020 Q1	$1.58M	Buy	+50,000	New	+$2.64M	﹤0.01%	2982
2019 Q3	–	Sell	-10,000	Closed	-$465K	–	8055
2019 Q2	$465K	Buy	+10,000	New	+$470K	﹤0.01%	4345

Other funds holding ESPR

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

UBS Group's ESPR Position: Q3 2026 in Review

UBS Group sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 3,836,202 shares — an estimated $12.1M sold.

UBS Group first reported a position in ESPR in Q4 2014 and held it in 47 quarters. The position peaked at $12.1M in Q2 2026. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

UBS Group reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
UBS Group sold 3,836,202 Esperion Therapeutics shares in Q3 2026, an estimated $12.1M.
UBS Group first reported a position in Esperion Therapeutics in Q4 2014 and held it in 47 quarters.
UBS Group's Esperion Therapeutics position peaked at $12.1M in Q2 2026.
2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.